Ebrotidine | FI-3542 | CAS#100981-43-9 | H2 receptor antagonist

Ebrotidine
featured

WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 326740

CAS#: 100981-43-9

Description: Ebrotidine, also known as FI-3542, is an H2 receptor antagonist with gastroprotective activity against ethanol-, aspirin- or stress-induced gastric mucosal damage. The antisecretory properties of ebrotidine are similar to those of ranitidine, and approximately 10-fold greater than those of cimetidine. Ebrotidine has anti-Helicobacter pylori activity via inhibition of the urease enzyme and the proteolytic and mucolytic activities of the bacterium. However, its activity is synergistic with a number of antibacterial agents. Ebrotidine counteracts the inhibitory effects of H. pylori lipopolysaccharides. Ebrotidine has been shown to be as effective as ranitidine for the treatment of gastric or duodenal ulcers or erosive reflux oesophagitis, with significantly better ulcer healing rates (albeit inexplicably) in those who smoke.

Chemical Structure

Ebrotidine

CAS# 100981-43-9

Instruction

Theoretical Analysis

MedKoo Cat#: 326740
Name: Ebrotidine
CAS#: 100981-43-9
Chemical Formula: C14H17BrN6O2S3
Exact Mass: 475.98
Molecular Weight: 477.414
Elemental Analysis: C, 35.22; H, 3.59; Br, 16.74; N, 17.60; O, 6.70; S, 20.15

Price and Availability

Size	Price	Availability
10mg	USD 320	2 Weeks
50mg	USD 750	2 weeks
Bulk inquiry Welcome, Customer: Please do not inquire quote if your intended use is for a patient since our products are for research use and for chemical synthesis use, not for human use . For in-stock products, we listed price in the web page. You may inquire prices for which sizes were not listed. If no price is listed, this means the product is not in stock at the moment, which may be available via custom synthesis. For cost-effective reason, minimum order of 1g is requested (typically very expensive). The lead time is usually 2-4 months. Quote of less than 1g will not be provided. MedKoo may not offer quote for below reasons: (1) current available synthetic method appears to be extremely expensive which is obviously not affordable to most customers; (2) Key raw material to make the product is temporally not available; (3) DEA controlled substances; (4) the product is under patent protection in customer’s country.

Synonym: FI-3542; FI 3542; FI3542; Ebrotidine.

IUPAC/Chemical Name: (E)-N'-((4-bromophenyl)sulfonyl)-N-(2-(((2-guanidinothiazol-4-yl)methyl)thio)ethyl)formimidamide

InChi Key: ZQHFZHPUZXNPMF-UHFFFAOYSA-N

InChi Code: InChI=1S/C14H17BrN6O2S3/c15-10-1-3-12(4-2-10)26(22,23)19-9-18-5-6-24-7-11-8-25-14(20-11)21-13(16)17/h1-4,8-9H,5-7H2,(H,18,19)(H4,16,17,20,21)

SMILES Code: O=S(C1=CC=C(Br)C=C1)(/N=C/NCCSCC2=CSC(NC(N)=N)=N2)=O

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO

Shelf Life: >2 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

More Info:

Instruction:

View handling instruction

Biological target:
In vitro activity:
In vivo activity:

Preparing Stock Solutions

The following data is based on the product molecular weight 477.41 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

Formulation protocol:
In vitro protocol:
In vivo protocol:

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.

Mass

Concentration

Volume

M. Wt* g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

Volume (to add to vial)

Mass (in vial)

Desired Reconstitution Concentration

Dilution Calculator

Calculate the dilution required to prepare a stock solution.

Concentration 1

Volume 1

Concentration 2

Volume 2

1: Sentellas S, Puignou L, Galceran MT. Determination of ebrotidine and its metabolites by micellar electrokinetic capillary chromatography. J Chromatogr A. 2002 Nov 8;976(1-2):221-7. PubMed PMID: 12462613.

2: Sentellas S, Saurina J, Hernández-Cassou S, Galceran MT, Puignou L. Determination of ebrotidine metabolites in overlapping peaks from capillary zone electrophoresis using chemometric methods. Electrophoresis. 2001 Jan;22(1):71-6. PubMed PMID: 11197182.

3: Sentellas S, Puignou L, Moyano E, Galceran MT. Determination of ebrotidine and its metabolites by capillary electrophoresis with UV and mass spectrometry detection. J Chromatogr A. 2000 Aug 4;888(1-2):281-92. PubMed PMID: 10949494.

4: Castillo JR, Torelló J, Hernandez A. Liver injury caused by ebrotidine: a new example of the utility of the postmarketing surveillance. Eur J Clin Pharmacol. 2000 May;56(2):187-9. PubMed PMID: 10877015.

5: Arroyo MT, Lanas A, Sáinz R. Prevention and healing of experimental indomethacin-induced gastric lesions: effects of ebrotidine, omeprazole and ranitidine. Eur J Gastroenterol Hepatol. 2000 Mar;12(3):313-8. PubMed PMID: 10750652.

6: Quílez C, Palazón JM, Jover R, Martínez R, Chuliá T, Griñó P, Belda G. [Hepatoxicity due to ebrotidine: report of two cases]. Gastroenterol Hepatol. 1999 Oct;22(8):434-5. Spanish. PubMed PMID: 10592681.

7: Slomiany BL, Piotrowski J, Slomiany A. Effect of ebrotidine on gastric mucosal inflammatory responses to Helicobacter pylori lipopolysaccharide. J Physiol Pharmacol. 1999 Sep;50(3):391-404. PubMed PMID: 10574469.

8: Pineda JA, Larrauri J, Macías J, Hernández A, Guijarro J, Sayago M, Gavilán F, Aguilar J, Lissen E. Rapid progression to liver cirrhosis of toxic hepatitis due to ebrotidine. J Hepatol. 1999 Oct;31(4):777-8. PubMed PMID: 10551406.

9: Andrade RJ, Lucena MI, Martin-Vivaldi R, Fernandez MC, Nogueras F, Pelaez G, Gomez-Outes A, Garcia-Escaño MD, Bellot V, Hervás A, Cárdenas F, Bermudez F, Romero M, Salmerón J. Acute liver injury associated with the use of ebrotidine, a new H2-receptor antagonist. J Hepatol. 1999 Oct;31(4):641-6. PubMed PMID: 10551387.

10: Carretero Aníbarro P, Blanco Carmona J, García González F, Garcés Sotillos M, Herrero Gil D, Pérez Giménez R, Juste Picón S. Allergic dermatitis due to oral ebrotidine. J Investig Allergol Clin Immunol. 1999 May-Jun;9(3):193-4. PubMed PMID: 10412683.

11: Rausell V, Hallal H, Salinas E, Pérez-Gracia A. [Ebrotidine-induced acute hepatitis]. Gastroenterol Hepatol. 1999 Jan;22(1):28. Review. Spanish. PubMed PMID: 10089709.

12: Romero A, Villamayor F, Rives A, Grau MT, Sacristán A, Ortiz JA. Twenty-four-month oral carcinogenicity study of ebrotidine in rats. Teratog Carcinog Mutagen. 1998;18(6):263-77. PubMed PMID: 10052562.

13: Castellote J, Porta F. [Toxic hepatitis caused by ebrotidine]. Med Clin (Barc). 1998 Nov 21;111(17):676. Spanish. PubMed PMID: 9881355.

14: Fernández Bermejo M, García Grávalos R. [Ebrotidine in the eradicating treatment of H. pylori]. Gastroenterol Hepatol. 1998 Jun-Jul;21(6):316. Spanish. PubMed PMID: 9711019.

15: Alarcón T, Domingo D, Sánchez I, Sanz JC, Martínez MJ, López-Brea M. In vitro activity of ebrotidine, ranitidine, omeprazole, lansoprazole, and bismuth citrate against clinical isolates of Helicobacter pylori. Eur J Clin Microbiol Infect Dis. 1998 Apr;17(4):275-7. PubMed PMID: 9707312.

16: Slomiany BL, Piotrowski J, Slomiany A, Konturek JW, Domschke WW. Enhancement in the protective qualities of gastric mucus with combination therapy of ebrotidine and amoxicillin for H. pylori eradication. Gen Pharmacol. 1998 Aug;31(2):227-31. PubMed PMID: 9688464.

17: Slomiany BL, Piotrowski J, Slomiany A. Cell cycle progression during gastric ulcer healing by ebrotidine and sucralfate. Gen Pharmacol. 1997 Sep;29(3):367-70. PubMed PMID: 9378241.

18: Grover JK, Rathi SS, Vats V. Ebrotidine--a nostrum for ulcer. Trop Gastroenterol. 1997 Jul-Sep;18(3):111-3. Review. PubMed PMID: 9385853.

19: Slomiany BL, Piotrowski J, Slomiany A. Induction of tumor necrosis factor-alpha and apoptosis in gastric mucosal injury by indomethacin: effect of omeprazole and ebrotidine. Scand J Gastroenterol. 1997 Jul;32(7):638-42. PubMed PMID: 9246701.

20: Piotrowski J, Skrodzka D, Slomiany A, Slomiany BL. Reversal of gastric somatostatin receptor inhibition by Helicobacter pylori lipopolysaccharide with ebrotidine and sulglycotide. Gen Pharmacol. 1997 May;28(5):705-8. PubMed PMID: 9184806.

Your view history

Ebrotidine featured